Post-chemotherapy neutropenic fever
Internist's view
Versandkostenfrei!
Versandfertig in 6-10 Tagen
18,99 €
inkl. MwSt.
PAYBACK Punkte
9 °P sammeln!
There are currently no studies to support the use of Ceftazidime/amikacin-based regimen as first choice empirical treatment in patients with neutropenic fever.Demonstrate that the caftazidime/amikacin regimen is not the best empirical therapeutic approach, and could be directly impacting on longer recovery time, longer hospital stay, higher costs.
Andere Kunden interessierten sich für
